Technical Analysis for C4XD - C4X Discovery Holdings plc

Grade Last Price % Change Price Change
C 40.5 -2.41% -1.00
C4XD closed down 2.41 percent on Tuesday, May 11, 2021, on 46 percent of normal volume. It was able to find support at its 50 day moving average.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Down
Historical C4XD trend table...

Date Alert Name Type % Chg
50 DMA Support Bullish 0.00%
20 DMA Resistance Bearish -2.41%
20 DMA Resistance Bearish -2.41%
Bullish Engulfing Bullish -2.41%
Crossed Above 50 DMA Bullish -2.41%
Expansion Pivot Buy Setup Bullish Swing Setup -2.41%
Pocket Pivot Bullish Swing Setup -2.41%
Multiple of Ten Bullish Other -2.41%
Lower Bollinger Band Touch Weakness -2.41%
Fell Below 50 DMA Bearish 7.28%
Older End-of-Day Signals for C4XD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


C4X Discovery Holdings plc Description

C4X Discovery Holdings plc is a drug discovery and development company. The Company is engaged in the provision of technologies to improve the drug discovery process for small molecule therapies. Its discovery portfolio targets addiction, diabetes, inflammatory diseases and oncology, and includes small molecule versions of marketed biologics. Its products include Orexin-1, NRF-2, GPR142, GLP-1, Anti-IL-17, SGC Collaboration and Target 1. Its primary indication for its oral Orexin-1 antagonists is for the treatment of nicotine addiction as an aid to smoking cessation. It has two drug discovery programs targeting inflammatory disorders: oral Nrf-2 activators for the treatment of Chronic Obstructive Pulmonary disease (COPD) and oral/topical IL-17 inhibitors for the treatment of Psoriasis. IL-17 is implicated in multiple inflammatory and autoimmune diseases. Its suite of technologies include Taxonomy3, Conformetrix and MolPlex.


Sector: Healthcare
Industry: Biotechnology
Keywords: Life Sciences Biology Biopharmaceutical Drug Discovery Health Sciences Autoimmune Diseases Chronic Obstructive Pulmonary Disease Diabetes Inflammatory Disorders Psoriasis

Is C4XD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 54.5
52 Week Low 10.1
Average Volume 871,100
200-Day Moving Average 27.87
50-Day Moving Average 40.34
20-Day Moving Average 41.48
10-Day Moving Average 40.88
Average True Range 2.65
ADX 37.86
+DI 32.35
-DI 17.91
Chandelier Exit (Long, 3 ATRs ) 46.55
Chandelier Exit (Short, 3 ATRs ) 44.45
Upper Bollinger Band 44.56
Lower Bollinger Band 38.39
Percent B (%b) 0.34
BandWidth 14.87
MACD Line 0.11
MACD Signal Line 0.37
MACD Histogram -0.261
Fundamentals Value
Market Cap 91.67 Million
Num Shares 226 Million
EPS -5.00
Price-to-Earnings (P/E) Ratio -8.10
Price-to-Sales 0.00
Price-to-Book 4.30
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 42.60
Resistance 3 (R3) 42.67 42.03 42.25
Resistance 2 (R2) 42.03 41.50 42.00 42.13
Resistance 1 (R1) 41.27 41.17 40.95 41.20 42.02
Pivot Point 40.63 40.63 40.48 40.60 40.63
Support 1 (S1) 39.87 40.10 39.55 39.80 38.98
Support 2 (S2) 39.23 39.77 39.20 38.87
Support 3 (S3) 38.47 39.23 38.75
Support 4 (S4) 38.40